Clesrovimab approved by FDA for RSV prevention in infants

Current AATD management strategies include lifestyle modifications. For example, smoking accelerates lung disease so patients should be directed to stop smoking. Obesity and alcohol promote liver fibrosis, so maintaining a healthy body weight and avoiding alcohol is recommended. 🫁 As previously mentioned, augmentation therapy is indicated for specific patients with AATD-related lung disease. Several vaccinations can be considered in terms of preventing lung infection and liver disease (hepatitis A and hepatitis B viruses).14 In this module, a gastroenterology/hepatology expert discusses the pathophysiology of alpha-1 antitrypsin deficiency (AATD), importance of early diagnosis, multidisciplinary management strategies, and data on emerging therapies for treating AATD and its related liver and lung diseases. Review the full module here and earn CE/CME: https://bit.ly/4mOEaxC #CE #CME #MedicalEducation

𝗥𝗦𝗩 𝗦𝗲𝗮𝘀𝗼𝗻 𝗶𝘀 𝗖𝗼𝗺𝗶𝗻𝗴: 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗶𝗻 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗻𝗴 𝗦𝗲𝘃𝗲𝗿𝗲 𝗥𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗜𝗹𝗹𝗻𝗲𝘀𝘀 𝗶𝗻 𝗢𝗹𝗱𝗲𝗿 𝗔𝗱𝘂𝗹𝘁𝘀 Respiratory Syncytial Virus (#RSV) is a common, highly contagious pathogen typically recognized as a primary cause of severe lower respiratory tract disease in infants and young children. However, its significant burden on the #elders (aged 60 and above) has become increasingly evident. In this population, RSV infection frequently leads to severe lower respiratory tract disease , often requiring emergency medical intervention and prolonged hospitalization. The subsequent risk of mortality, coupled with the exacerbation of underlying chronic conditions like chronic obstructive pulmonary disease and congestive heart failure, makes RSV a major public health threat comparable to influenza. Given this substantial morbidity and mortality, the development and recent approval of RSV fusion (F) protein-based #vaccines represents a monumental step forward in proactive public health measures. These vaccines are designed to induce a robust neutralizing antibody response, primarily targeting the highly immunogenic pre-fusion conformation of the F protein. A recent pivotal clinical trial funded by #Pfizer demonstrated that receiving the #RSVpreF vaccine significantly reduced the incidence of: 🔸RSV-related respiratory tract disease hospitalization by 83.3% 🔸RSV-related lower respiratory tract disease hospitalization by 91.7% These results confirm the vaccine's high efficacy and provide a solid foundation for its recommendation in vulnerable older populations. Reference DOI: 10.1056/NEJMoa2509907

Phase 1 vaccine trial for infectious disease: 60 patients enrolled in one month! From activation to full enrollment in just one month, Confidence delivered record speed without compromising quality. Site activation in the U.S. was achieved in only 3 weeks — including full EDC build — thanks to streamlined startup processes and strong site communication. The sponsor highlighted this study as proof that early-phase trials don’t need to drag. This is how planning should be — clear, realistic, and built to deliver results. #ClinicalTrials #VaccineStudies #CRO #ClinicalHighlights #VaccineTrials

Emerging, challenging, and critical: Thyroid eye disease is one of the newest frontiers in Ora’s portfolio. The challenge: TED’s wide-ranging symptoms and variable progression make consistent endpoints and reliable measurements tough to achieve. Our approach: Ora combines deep ophthalmic trial expertise with rigorous imaging, clinical assessments, and standardised protocols to bring clarity to this complex indication. By partnering closely with investigators and sponsors, we help accelerate therapies that improve outcomes for patients living with TED. From our roots in ocular allergy to emerging indications like TED, Ora continues to lead with innovation and patient focus. #IndicationSpotlight #ThyroidEyeDisease #OphthalmologyResearch #ClinicalTrials #TeamOra

Home-Based Ig Therapy: Fewer Infections, Less Antibiotics 💉🏠 Adults with primary immunodeficiency diseases (PIDDs) who self-administer immunoglobulin replacement therapy (IgRT) at home experience: ✅ Lower infection rates (83% vs 90%) ✅ Reduced antibiotic use (81% vs 87%) The convenience of self-administered Ig therapy at home empowers patients while improving outcomes. A real win for independence and health! Learn more: 🔗 https://lnkd.in/erKSpuQs #PrimaryImmunodeficiency #IgTherapy #HomeCare #PatientOutcomes #Immunology #SpecialtyPharmacy

Our paper “Expanding the Spectrum of Selective IgM Deficiency: From Infections to Immune Dysregulation” has just been published in International Journal of Molecular Sciences. We studied 39 pediatric patients with isolated IgM deficiency — including both those with recurrent infections (sIgMD) and those who did not present with infections (IgMD) and found that immune dysregulation markers — such as cytopenias, autoimmunity, allergy, inflammation, and lymphoproliferation — occur at similar rates in both groups. This challenges the assumption that infection history must be part of sIgMD definitions. IgM trajectories over time are dynamic: some patients show chronic deficiency, others intermittent or progressive decline, and a few even normalization. Notably, molecular diagnoses of inborn errors of immunity (IEIs) were established in both groups, even among patients without infections — suggesting that IgM deficiency may be a wider immunological flag than previously thought. I believe these findings may help us re-think how we define IgM deficiency and trigger follow-up and genetic testing even in the absence of infections. You can read the full study here: https://lnkd.in/d7XraPRB

It’s Cough Awareness Day. Let let me make us aware of the real hope shaping up on the horizon. For years, chronic cough was treated like background noise in medicine, a vexing symptom chasing other diseases. At #ERS2025, that changed. Across multiple sessions, the world’s cough experts agreed: chronic cough isn’t just a symptom anymore. It’s a disease—a hypersensitivity disorder of the airways and brain pathways that control the reflex to cough. And for patients who’ve coughed for months or years, that recognition finally brings hope. Several global trials, most notably with gefapixant (the first P2X3 inhibitor) have shown meaningful improvement in cough frequency and quality of life. In many patients, the relief was felt within days and sustained for months. The catch? The placebo effect was enormous, often 40% sometimes up to 60 percent. When patients finally feel heard, cared for, and followed, they often get better even without the active drug. That’s beautiful for patients, but a nightmare for researchers designing the next trial. Still, momentum is building. Europe now has specialized cough clinics, new diagnostic frameworks, and early moves toward re-classifying chronic cough in ICD-12 as its own disease. Speech therapy, neuromodulators, and the next generation of targeted antitussives are forming a layered approach, treating cough not as a noise to silence, but as a signal from a sensitized nervous system that can be retrained. For the millions who live with relentless coughing, there’s real progress in sight. The challenge for science is to separate hope from mechanism, and find treatments that work even after the placebo fades. christian domingo ribas Jan Willem van den Berg SONG WOO JUNG Francesca Polverino Photo credit: Global Allergy & Airways Patient Platform Thank you for the reminder Farrell Simon

“When Influenza Hides Behind Unusual Symptoms: Why Doctors Must Think Beyond the Lungs” Physicians should maintain a high index of suspicion for influenza even when patients present with non-respiratory or atypical symptoms, particularly during peak flu seasons. Influenza can masquerade as gastrointestinal, neurological, cardiac, or systemic illnesses, leading to delayed diagnosis and inappropriate management. Cases presenting with acute diarrhea, vomiting, myalgia, confusion, myocarditis, or unexplained fever without prominent cough or sore throat may still represent influenza infection. Early recognition through comprehensive clinical assessment and timely diagnostic testing is crucial to initiate antiviral therapy promptly, prevent complications, and reduce transmission. Awareness of these atypical manifestations is essential for early case detection, rational antibiotic use, and improved patient outcomes, especially among vulnerable groups such as the elderly, immunocompromised, and those with chronic illnesses.

World MRSA Day (October 2) reminds us that methicillin-resistant Staphylococcus aureus (MRSA) remains to be one of the most persistent superbugs fueling the global fight against antimicrobial resistance (AMR). MRSA continues to be a leading cause of hospital-associated infections, with high morbidity, mortality rates, and healthcare burden. Delayed test results often lead to empiric therapy—further exacerbating the AMR crisis. In our new clinical perspective article (Title: World MRSA Day: A Fight Against Antimicrobial Resistance) by Pallavi Upadhyay, PhD, CMPP, we explore why timely and accurate detection through molecular PCR testing is critical. PCR rapidly identifies MRSA within hours, enabling targeted treatment, reducing unnecessary antibiotic use, and helping curb AMR. The World MRSA Day is observed not only to raise awareness about MRSA spread but also to promote timely testing, antibiotic stewardship, and continued research to combat superbugs and antimicrobial resistance. By combining vigilance, prevention, and rapid diagnostics, we can better protect patients and reduce the impact of this dangerous superbug Read Full article here: https://lnkd.in/gwNfaSVA #WorldMRSADay #AMR #PCRtesting #MolecularDiagnostics #Clinicaldiagnostics #superbugs #InfectiousDiseases